NCT05821374撤回早期 1 期
Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 撤回
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Change in Physician's Global Assessment (PGA)
研究概览
简要总结
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women between the ages of 18-70 years old
- •Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor criteria
- •Women must not be pregnant, lactating, or planning pregnancy during the study period
- •Women of child-bearing potential must be on birth control for the duration of the treatment period.
- •Subjects must agree to the use of at least one of the following contraception methods for the entire duration of the study until at least 30 days after taking their last dose of study drug:
- •Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring); Spiral (with or without hormones); any sterilization methods; a partner who has had a vasectomy; or sexual abstinence.
- •Other acceptable methods of contraception are male or female condoms (with or without spermicide) or a cap, diaphragm, or sponge with spermicide.
- •Willing to discontinue topical and/or systemic therapies, with the exception of oral rescue therapy with steroids.
- •The wash period for systemic therapies will largely depend on the specific treatment but, in general, will be at least 6 months for biologics and 3 months for other immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc. No wash out period is required for topicals.
- •Capable and willing to sign Institutional Review Board/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures.
排除标准
- •Patient under 18 years of age.
- •Patients with a history of inflammatory bowel disease.
- •Patients on systemic immunosuppressive/immune modulating therapy including: oral steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFα inhibitor at time of starting deucravacitinib.
- •Patients currently enrolled in another investigational study.
- •Patients with a history or evidence of active infection and/or febrile illness within 7 days; or serious infection requiring antibiotic treatment within 30 days
- •Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for HCV RNA detectable by polymerase chain reaction (PCR)
- •Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface antigen or for HBV DNA detectable by PCR
- •Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive
- •History of active or inadequately treated latent tuberculosis (TB)
- •Known or suspected systemic or skin autoimmune disorder other than pyoderma gangrenosum
- •Any unstable major illness or evidence of unstable condition of major organ systems including psychiatric
- •Cancer or history of lymphoproliferative disease within last 5 years; exception is cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.
- •Major surgery within the last 4 weeks
- •Live vaccines within the last 60 days
- •Leukopenia (absolute WBC count < 3000/mm3); Lymphopenia (ALC < 500/mm3); Neutropenia (ANC < 1000/mm3)
- •Thrombocytopenia (platelet count < 100,000/mm3; Anemia (hemoglobin < 9.0g/dL)
- •ALT/AST > 3 X ULN and/or Total, unconjugated, and/or conjugated bilirubin > 2 X ULN within 28 days of dosing
研究组 & 干预措施
Deucravacitinib
Experimental
Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.
干预措施: Deucravacitinib (Drug)
结局指标
主要结局
Change in Physician's Global Assessment (PGA)
时间窗: Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
PGA will be used for overall assessment of efficacy.
Change from baseline in ulcer size measured by calculating the area of the ulcers in centimeters squared using a digital application.
时间窗: Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115
imitoAG application for mobile devices will be used to calculate the dimensions of the ulcers in centimeters to determine if the size of the ulcers is changed by the treatment.
次要结局
- The percentage of patients needing rescue therapy from baseline to Day 115(Baseline through Day 115)
研究者
Brian.J.Simmons
Director of Dermatology Research
Dartmouth-Hitchcock Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Deucravacitinib (BMS-986165) for Pityriasis Rubra PilarisPityriasis Rubra PilarisNCT06444399Mayo Clinic7
已完成
2 期
A Study of Deucravacitinib to Treat LPP and FFALichen PlanopilarisNCT06091956Mayo Clinic12
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeSjögren's SyndromeNCT05946941Bristol-Myers Squibb774
已完成
3 期
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental FatModerate to Severe Convexity of Submental FatSafetyEfficacyNCT02035267Kythera Biopharmaceuticals93
已完成
3 期
Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of AgeModerate to Severe Convexity of Submental FatSafetyEfficacyNCT02123134Kythera Biopharmaceuticals55